Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 20;6(6):CD003456.
doi: 10.1002/14651858.CD003456.pub3.

Drug therapy for chronic idiopathic axonal polyneuropathy

Janna Warendorf  1 , Alexander Fje Vrancken, Ivo N van Schaik, Richard Ac Hughes, Nicolette C Notermans
Affiliations

Drug therapy for chronic idiopathic axonal polyneuropathy

Janna Warendorf et al. Cochrane Database Syst Rev. .

Abstract

Background: Chronic idiopathic axonal polyneuropathy (CIAP) is an insidiously progressive sensory or sensorimotor polyneuropathy that affects elderly people. Although severe disability or handicap does not occur, CIAP reduces quality of life. CIAP is diagnosed in 10% to 25% of people referred for evaluation of polyneuropathy. There is a need to gather and review emerging evidence on treatments, as the number of people affected is likely to increase in ageing populations. This is an update of a review first published in 2004 and previously updated in 2006, 2008, 2011 and 2013.

Objectives: To assess the effects of drug therapy for chronic idiopathic axonal polyneuropathy for reducing disability and ameliorating neurological symptoms and associated impairments, and to assess any adverse effects of treatment.

Search methods: In July 2016, we searched Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews in the Cochrane Library, MEDLINE, Embase, and the Web of Science. We searched two trials registries for ongoing trials. We also handsearched the reference lists of relevant articles, reviews and textbooks identified electronically, and we would have contacted authors and other experts in the field to identify additional studies if this seemed useful.

Selection criteria: We sought all randomised or quasi-randomised (alternate or other systematic treatment allocation) trials that examined the effects of any drug therapy in people with CIAP at least one year after the onset of treatment. People with CIAP had to fulfil the following criteria: age 40 years or older, distal sensory or sensorimotor polyneuropathy, absence of systemic or other neurological disease, chronic clinical course not reaching a nadir in less than two months, exclusion of any recognised cause of the polyneuropathy by medical history taking, clinical or laboratory investigations, and electrophysiological studies in agreement with axonal polyneuropathy, without evidence of demyelinating features. The primary outcome was the proportion of participants with a significant improvement in disability. Secondary outcomes were change in the mean disability score, change in the proportion of participants who make use of walking aids, change in the mean Medical Research Council sum score, degree of pain relief and/or reduction of other positive sensory symptoms, change in the proportion of participants with pain or other positive sensory symptoms, and frequency of adverse effects.

Data collection and analysis: Two review authors independently reviewed the results of the literature search and extracted details of trial methodology and outcome data of all potentially relevant trials.

Main results: We identified 39 studies and assessed them for possible inclusion in the review, but we excluded all of them because of insufficient quality or lack of relevance. We summarised evidence from non-randomised studies in the Discussion.

Authors' conclusions: Even though CIAP has been clearly described and delineated, no adequate randomised or quasi-randomised controlled clinical treatment trials have been performed. In their absence there is no proven efficacious drug therapy.

PubMed Disclaimer

Conflict of interest statement

Janna Warendorf: none known.

Alexander Vranken: none known.

Ivo van Schaik: received departmental honoraria for serving on scientific advisory boards for CSL‐Behring, Baxter and UCB, and a speaker's fee from Kedrion and CSL‐Behring. He chairs a steering committee for CSL‐Behring.

Richard Hughes: none known.

Nicolette Notermans: none known.

Update of

Similar articles

See all similar articles

Cited by

References

References to studies excluded from this review

Attal 2016 {published data only}
    1. Attal N, Andrade DC, Adam F. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology 2016;15(6):555‐65. - PubMed
Bradley 1988 {published data only}
    1. Bradley WG, Badger GJ, Tandan R, Fillyaw MJ, Young J, Fries TJ, et al. Double‐blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia. Neurology 1988;38(11):1731‐9. [PUBMED: 2847079] - PubMed
De Grandis 1995 {published data only}
    1. Grandis D, Santoro L, Benedetto P. L‐acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double‐blind clinical study of 426 patients. Clinical Drug Investigation 1995;10(6):317‐22. [EMBASE: 1996006029] - PubMed
Demant 2014 {published data only}
    1. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain 2014;155(11):2263‐73. [PUBMED: 25139589] - PubMed
Frank 2008 {published data only}
    1. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008;336(7637):199‐201. [PUBMED: 18182416] - PMC - PubMed
Galer 2000 {published data only}
    1. Galer BS, Twilling LL, Harle J, Cluff RS, Friedman E, Rowbotham MC. Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions. Neurology 2000;55(7):971‐5. [PUBMED: 11061253] - PubMed
Gilron 2011 {published data only}
    1. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo‐controlled trial. Clinical Journal of Pain 2011;27(3):185‐93. [PUBMED: 21178603] - PubMed
Haanpaa 2016 {published data only}
    1. Haanpää M, Cruccu G, Nurmikko TJ, McBride WT, Docu Axelarad A, Bosilkov A, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. European Journal of Pain 2016;20(2):316‐28. - PMC - PubMed
Hewitt 2011 {published data only}
    1. Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, et al. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain 2011;152(3):514‐21. [PUBMED: 21185118] - PubMed
Ho 2008 {published data only}
    1. Ho KY, Huh BK, White WD, Yeh CC, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. The Clinical Journal of Pain 2008;24(1):51‐5. [PUBMED: 18180637] - PubMed
Ho 2009 {published data only}
    1. Ho TW, Backonja M, Ma J, Leibensperger H, Froman S, Polydefkis M. Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies. Pain 2009;141(1‐2):19‐24. [PUBMED: 19013718] - PubMed
Holbech 2011 {published data only}
    1. Holbech JV, Otto M, Bach FW, Jensen TS, Sindrup SH. The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo‐controlled, cross‐over trial. European Journal of Pain 2011;15(6):608‐14. [PUBMED: 21183370] - PubMed
Holbech 2015 {published data only}
    1. Holbech JV, Bach FW, Finnerup NB, Brøsen K, Jensen TS, Sindrup SH. Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. Pain 2015;156(5):958‐66. - PubMed
Huge 2010 {published data only}
    1. Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, et al. Effects of low‐dose intranasal (S)‐ketamine in patients with neuropathic pain. European Journal of Pain 2010;14(4):387‐94. [PUBMED: 19733106] - PubMed
Husstedt 1993 {published data only}
    1. Husstedt IW, Thümler R, Röder R, Dreyer M, Leopold W, Scheller W. Behandlung von Polyneuropathien. Untersuchungen zur Wirksamkeit von Ginkgo‐biloba‐Extrakt EGb 761 bei Patienten mit Polyneuropathie. Zeitschrift für Allgemeine Medizin 1993;69:714‐7. [EMBASE: 1993302831]
Jensen 2012 {published data only}
    1. Jensen MP, Gammaitoni AR, Bolognese JA, Alon A, Smugar SS, Galer BS, et al. The pain quality response profile of pregabalin in the treatment of neuropathic pain. Clinical Journal of Pain 2012;28(8):683‐6. [PUBMED: 22156827] - PubMed
Kishore‐Kumar 1989 {published data only}
    1. Kishore‐Kumar R, Schafer SC, Lawlor BA, Murphy DL, Max MB. Single doses of the serotonin agonists buspirone and m‐chlorophenylpiperazine do not relieve neuropathic pain. Pain 1989;37(2):223‐7. [PUBMED: 2664664] - PubMed
Langohr 1982 {published data only}
    1. Langohr HD, Stohr M, Petruch F. An open and double‐blind cross‐over study on the efficacy of clomipramine (Anafranil) in patients with painful mono‐ and polyneuropathies. European Neurology 1982;21(5):309‐17. [PUBMED: 6126361] - PubMed
Li 2010 {published data only}
    1. Li L. The effect of Neuragen PN on neuropathic pain: a randomized, double blind, placebo controlled clinical trial. BMC Complementary and Alternative Medicine 2010;10:22. [PUBMED: 20487567] - PMC - PubMed
Low 1995 {published data only}
    1. Low PA, Opfer‐Gehrking TL, Dyck PJ, Litchy WJ, O'Brien PC. Double‐blind, placebo‐controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 1995;62(2):163‐8. [PUBMED: 8545141] - PubMed
Maier 2002 {published data only}
    1. Maier C, Hildebrandt J, Klinger R, Henrich‐Ebert C, Lindena G, the MONTAS Study Group. Morphine responsiveness, efficacy and tolerability in patients with chronic no‐tumor associated pain ‐ results of a double‐blind placebo‐controlled trial (MONTAS). Pain 2002;97(3):223‐33. [PUBMED: 12044619] - PubMed
Meier 2003 {published data only}
    1. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double‐blind, placebo‐controlled study. Pain 2003;106(1‐2):151‐8. [PUBMED: 14581122] - PubMed
Morley 2003 {published data only}
    1. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low‐dose methadone has an analgesic effect in neuropathic pain: a double‐blind randomized controlled crossover trial. Palliative Medicine 2003;17(7):576‐87. [PUBMED: 14594148] - PubMed
NCT00156689 {unpublished data only}
    1. NCT00156689. A study to determine if levetiracetam will assist those suffering from chronic idiopathic axonal polyneuropathy [A pilot study in a double blind, randomized, placebo‐controlled, parallel‐group, 16 week, trial design evaluating the efficacy and safety of levetiracetam 500 mg tablets in bid administration (daily dose ranging from 1000 mg to 3000 mg), in adults (>18 years of ages) suffering from chronic idiopathic axonal polyneuropathy]. clinicaltrials.gov/ct2/show/NCT00156689 (first received 7 September 2005).
Nurmikko 2007 {published data only}
    1. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double‐blind, placebo‐controlled clinical trial. Pain 2007;133(1‐3):210‐20. [PUBMED: 17997224] - PubMed
Onofrj 1995 {published data only}
    1. Onofrj M, Fulgente T, Melchionda D, Marchionni A, Tomasello F, Salpietro FM, et al. L‐acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. International Journal of Clinical Pharmacology Research 1995;15(1):9‐15. [PUBMED: 7490173] - PubMed
Otto 2004 {published data only}
    1. Otto M, Bach FW, Jensen TS, Sindrup SH. Valproic acid has no effect in polyneuropathy. A randomized, controlled trial. Neurology 2004;62(2):285‐8. [PUBMED: 14745070] - PubMed
Otto 2008 {published data only}
    1. Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH. Escitalopram in painful polyneuropathy: a randomized, placebo‐controlled, cross‐over trial. Pain 2008;139(2):275‐83. [PUBMED: 18547727] - PubMed
Pedersen 2014 {published data only}
    1. Pedersen L, Borchgrevink PC, Breivik HP, Fredheim OM. A randomized, double‐blind, double‐dummy comparison of short‐ and long‐acting dihydrocodeine in chronic non‐malignant pain. Pain 2014;155(5):881‐8. [PUBMED: 24345428] - PubMed
Raber 2015 {published data only}
    1. Raber JM, Reichelt D, Gruneberg‐oelker U, Phillipp K, Stubbe‐Drager B, Husstedt I. Capsaicin 8% as a cutaneous patch (Qutenza™): analgesic effect on patients with peripheral neuropathic pain. Acta Neurological Belgica 2015;115(3):335‐43. - PubMed
Rauck 2006 {published data only}
    1. Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, et al. Ziconotide Study Group. A randomized, double‐blind, placebo‐controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of Pain and Symptom Management 2006;31(5):393‐406. [PUBMED: 16716870] - PubMed
Rowbotham 2003 {published data only}
    1. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. New England Journal of Medicine 2003;348(13):1223‐32. [PUBMED: 12660386] - PubMed
Semenchuk 2001 {published data only}
    1. Semenchuk MR, Sherman S, Davis B. Double‐blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001;57(9):1583‐8. [PUBMED: 11706096] - PubMed
Serpell 2014 {published data only}
    1. Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, et al. A double‐blind, randomized, placebo‐controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. European Journal of Pain 2014;18(7):999‐1012. [PUBMED: 24420962] - PubMed
Sindrup 1999a {published data only}
    1. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double‐blind, controlled trial. Pain 1999;83(1):85‐90. [PUBMED: 10506675] - PubMed
Sindrup 1999b {published data only}
    1. Sindrup SH, Madsen C, Brosen K, Jensen TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clinical Pharmacology and Therapeutics 1999;66(6):636‐41. [PUBMED: 10613620] - PubMed
Sindrup 2001 {published data only}
    1. Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John's wort has no effect on pain in polyneuropathy. Pain 2001;91(3):361‐5. [PUBMED: 11275394 ] - PubMed
Sindrup 2003 {published data only}
    1. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy. Neurology 2003;60(8):1284‐9. [PUBMED: 12707430] - PubMed
Sindrup 2012 {published data only}
    1. Sindrup SH, Konder R, Lehmann R, Meier T, Winkel M, Ashworth J, et al. Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. European Journal of Pain 2012;16(6):849‐59. [PUBMED: 22337471] - PubMed
Vrethem 1997 {published data only}
    1. Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindstrom T, Thorell. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clinical Journal of Pain 1997;13(4):313‐23. [PUBMED: 9430812] - PubMed
Wallace 2000 {published data only}
    1. Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double‐blind, placebo‐controlled, crossover study. Regional Anesthesia and Pain Medicine 2000;25(5):459‐67. [PUBMED: 11009230] - PubMed
Wallace 2002 {published data only}
    1. Wallace MS, Rowbotham M, Bennett GJ, Jensen TS, Pladna R, Quessy S. A multicenter, double‐blind, randomized, placebo‐controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. Journal of Pain 2002;3(3):227‐33. [PUBMED: 14622777] - PubMed
Wilsey 2013 {published data only}
    1. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low‐dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain 2013;14(2):136‐48. [PUBMED: 23237736] - PMC - PubMed
Windebank 2004 {published data only}
    1. Windebank AJ, Sorenson EJ, Civil R, O'Brien PC. Role of insulin‐like growth factor‐I in the treatment of painful small fiber predominant neuropathy. Journal of the Peripheral Nervous System 2004;9:183‐9. [PUBMED: 15363067] - PubMed

References to ongoing studies

NCT02260388 {published data only}
    1. NCT02260388. Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN‐CONTRoLS). clinicaltrials.gov/ct2/show/NCT02260388 (first received 6 October 2014).
NCT02597257 {published data only}
    1. Efficacy and safety of lidocaine infusion treatment in management of neuropathic pain: randomized, controlled, comparative study [Efficacy and safety of lidocaine infusion treatment in management of neuropathic pain]. clinicaltrials.gov/ct2/show/NCT02597257 (first received 18 September 2015).

Additional references

Ang 2008
    1. Ang CD, Alviar MJ, Dans AL, Bautista‐Velez GG, Villaruz‐Sulit MV, Tan JJ, et al. Vitamin B for treating peripheral neuropathy. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD004573.pub3; PUBMED: 18646107] - DOI - PubMed
Attal 2010
    1. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113‐e88. [PUBMED: 20402746] - PubMed
Attal 2015
    1. Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?. Pain 2015;156 Suppl 1:S104‐14. [PUBMED: 25789426] - PubMed
Baldereschi 2013
    1. Baldereschi M, Inzitari M, Carlo A, Bovis F, Maggi S, Capurso A, et al. Vascular factors predict polyneuropathy in a non‐diabetic elderly population. Neurological Sciences 2013;34(6):955‐62. [PUBMED: 22893359] - PubMed
Bays 2006
    1. Bays H. Statin safety: an overview and assessment of the data‐‐2005. American Journal of Cardiology 2006;97(8A):6C‐26C. [PUBMED: 16581330] - PubMed
Bhalla 2014
    1. Bhalla S, Singh N, Jaggi AS. Statins: do they aggravate or ameliorate neuropathic pain?. Journal of Pain 2014;15(11):1069‐80. [PUBMED: 25086324] - PubMed
Camerlingo 1998
    1. Camerlingo M, Nemni R, Ferraro B, Casto L, Partziguian T, Censori B, et al. Malignancy and sensory neuropathy of unexplained cause: a prospective study of 51 patients. Archives of Neurology 1998;55:981‐4. - PubMed
Cameron 2001
    1. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44(11):1973‐88. - PubMed
Cepeda 2006
    1. Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. Journal of Pain 2006;7(2):119‐28. - PubMed
Challapalli 2005
    1. Challapalli V, Tremont‐Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003345.pub2; PUBMED: 16235318] - DOI - PMC - PubMed
Chaparro 2012
    1. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD008943.pub2; PUBMED: 22786518] - DOI - PMC - PubMed
Chia 1996
    1. Chia L, Fernandez A, Lacroix C, Plante V, Said G. Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients. Brain 1996;119:1091‐8. - PubMed
Cohen 2014
    1. Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ 2014;348:f7656. [PUBMED: 24500412] - PubMed
Deprez 2000
    1. Deprez M, Groote CC, Gollogly L, Reznik M, Martin JJ. Clinical and neuropathological parameters affecting the diagnostic yield of nerve biopsy. Neuromuscular Disorders 2000;10(2):92‐8. - PubMed
Derry 2013
    1. Derry S, Rice Andrew S C, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3; PUBMED: 24217986] - DOI - PMC - PubMed
Derry 2015
    1. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD011789; PUBMED: 26148202] - DOI - PMC - PubMed
Duehmke 2006
    1. Duehmke RM, Hollingshead J, Cornblath DR. Tramadol for neuropathic pain. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD003726.pub3; PUBMED: 16856016] - DOI - PubMed
Dyck 1981
    1. Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Annals of Neurology 1981;10:222‐6. - PubMed
Eliasson 2003
    1. Eliasson B. Cigarette smoking and diabetes. Progression in Cardiovascular Disease 2003;45(5):405‐13. - PubMed
Erdmann 2010
    1. Erdmann PG, Genderen FR, Teunissen LL, Notermans NC, Lindeman E, Wijck AJ, et al. Pain in patients with chronic idiopathic axonal polyneuropathy. European Neurology 2010;64(1):58‐64. [PUBMED: 20634621] - PubMed
Farhad 2015
    1. Farhad K, Traub R, Ruzhansky KM, Brannagan TH 3rd. Causes of neuropathy in patients referred as "idiopathic neuropathy". Muscle & Nerve 2016;53(6):858‐61. [DOI: 10.1002/mus.24969; PUBMED: 26561790] - DOI - PubMed
Finnerup 2015
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology 2015;14(2):162‐73. [PUBMED: 25575710] - PMC - PubMed
Forrest 1997
    1. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997;46(4):665‐70. - PubMed
Fressinaud 2003
    1. Fressinaud C, Jean I, Dubas F. Selective decrease in axonal nerve growth factor and insulin‐like growth factor I immunoreactivity in axonopathies of unknown etiology. Acta Neuropathologica (Berlin) 2003;105(5):477‐83. - PubMed
Gabriel 2000
    1. Gabriel CM, Howard R, Kinsella N, Lucas S, McColl I, Saldanha G, et al. Prospective study of the usefulness of sural nerve biopsy. Journal of Neurology, Neurosurgery, and Psychiatry 2000;69:442‐6. - PMC - PubMed
Gilron 2014
    1. Gilron I, Dickenson AH. Emerging drugs for neuropathic pain. Expert Opinion on Emerging Drugs 2014;19(3):329‐41. [PUBMED: 24793304] - PubMed
Graham 2006a
    1. Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(8):973‐6. - PMC - PubMed
Graham 2006b
    1. Graham RC, Hughes RAC. Clinimetric properties of a walking scale in peripheral neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(8):977‐9. - PMC - PubMed
Grahmann 1991
    1. Grahmann F, Winterholler M, Neundörfer B. Cryptogenetic polyneuropathies: an out‐patient follow‐up study. Acta Neurologica Scandinavica 1991;84:221‐5. - PubMed
Hernandez‐Ojeda 2014
    1. Hernandez‐Ojeda J, Roman‐Pintos LM, Rodriguez‐Carrizalez AD, Troyo‐Sanroman R, Cardona‐Munoz EG, Alatorre‐Carranza Mdel P, et al. Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double‐blind, placebo‐controlled Phase IIa study. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014;7:401‐7. [PUBMED: 25214797] - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hughes 2004
    1. Hughes RAC, Umapathi T, Gray IA, Gregson NA, Noori M, Pannala AS, Proteggente A, Swan AV. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004;127(Pt 8):1723‐30. - PubMed
Höke 2005
    1. Höke A, Keswani SC. Neuroprotection in the PNS: erythropoietin and immunophilin ligands. Annals of the New York Academy of Sciences 2005;1053:491‐501. [PUBMED: 16179557] - PubMed
Jann 1998
    1. Jann S, Gatti A, Crespi S, Rolo J, Beretta S. Peripheral neuropathy in chronic respiratory insufficiency. Journal of the Peripheral Nervous System 1998;3(1):69‐74. - PubMed
Jann 2001
    1. Jann S, Beretta S, Bramerio M, Defanti CA. Prospective follow‐up study of chronic polyneuropathy of undetermined cause. Muscle & Nerve 2001;24(9):1197‐201. - PubMed
Kleyweg 1991
    1. Kleyweg RP, Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barre syndrome. Muscle & Nerve 1991;14:1103‐9. - PubMed
Lehmann 2010
    1. Lehmann HC, Höke A. Schwann cells as a therapeutic target for peripheral neuropathies. CNS & Neurological Disorders Drug Targets 2010;9(6):801‐6. [PUBMED: 20874704] - PMC - PubMed
Leinninger 2004
    1. Leinninger GM, Vincent AM, Feldman EL. The role of growth factors in diabetic peripheral neuropathy. Journal of the Peripheral Nervous System 2004;9(1):26‐53. - PubMed
Lindh 2005
    1. Lindh J, Tondel M, Österberg A, Vrethem M. Cryptogenic polyneuropathy: clinical and neurophysiological findings. Journal of the Peripheral Nervous System 2005;10(1):31‐7. - PubMed
Lindh 2011a
    1. Lindh J, Tondel M, Persson B, Vrethem M. Health‐related quality of life in patients with cryptogenic polyneuropathy compared with the general population. Disability and Rehabilitation 2011;33(7):617‐23. [PUBMED: 20690857] - PubMed
Lindh 2011b
    1. Lindh J, Soderkvist P, Fredrikson M, Hosseininia S, Tondel M, Persson B, et al. Polymorphisms of GSTT1, GSTM1, and EPHX genotypes in patients with cryptogenic polyneuropathy: a case‐control study. Brain and Behavior 2011;1(2):135‐41. [PUBMED: 22399093] - PMC - PubMed
Logigian 1994
    1. Logigian EL, Kelly JJ, Jr, Adelman LS. Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy. Muscle & Nerve 1994;17(9):1010‐20. - PubMed
Malik 2000
    1. Malik RA. Can diabetic neuropathy be prevented by angiotensin‐converting enzyme inhibitors?. Annals of Medicine 2000;32(1):1‐5. - PubMed
Markman 2006
    1. Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. Journal of Pain 2006;7(15 Supplement 1):S38‐S47. - PubMed
McLeod 1984
    1. McLeod JG, Tuck RR, Pollard JD, Cameron J, Walsh JC. Chronic polyneuropathy of undetermined cause. Journal of Neurology, Neurosurgery, and Psychiatry 1984;47(5):530‐5. [PUBMED: 1027832] - PMC - PubMed
McNicol 2013
    1. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006146.pub2; PUBMED: 23986501] - DOI - PMC - PubMed
Merkies 2006
    1. Merkies ISJ, Lauria G. 131st ENMC International workshop: selection of outcome measures for peripheral neuropathy clinical trials, 10‐12 December, Naarden, The Netherlands. Neuromuscular Disorders 2006;16:149‐56. - PubMed
Miller 2012
    1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD001447.pub3; PUBMED: 22419278] - DOI - PMC - PubMed
Moore 2015a
    1. Moore RA, Kalso EA, Wiffen PJ, Derry S, Tölle TR, Finnerup NB, et al. Antidepressant drugs for neuropathic pain ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD011606] - DOI
Moore 2015b
    1. Moore RA, Wiffen PJ, Derry S, Lunn MP. Zonisamide for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD011241.pub2; PUBMED: 25879104] - DOI - PMC - PubMed
Moore 2015c
    1. Moore RA, Chi CC, Wiffen PJ, Derry S, Rice AS. Oral nonsteroidal anti‐inflammatory drugs for neuropathic pain. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD010902.pub2; PUBMED: 26436601] - DOI - PMC - PubMed
Müller 2005
    1. Müller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nature Reviews Drug Discovery 2005;4(5):387‐98. - PubMed
Nebuchennykh 2008
    1. Nebuchennykh M, Loseth S, Jorde R, Mellgren SI. Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series. European Journal of Neurology 2008;15(8):810‐6. [PUBMED: 18549398] - PubMed
Notermans 1993
    1. Notermans NC, Wokke JHJ, Franssen H, Graaf Y, Vermeulen M, Berg LH, et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. Journal of Neurology, Neurosurgery, and Psychiatry 1993;56:1066‐71. - PMC - PubMed
Notermans 1994
    1. Notermans NC, Wokke JHJ, Graaf Y, Franssen H, Dijk GW, Jennekens FG. Chronic idiopathic axonal polyneuropathy: a five year follow up. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57:1525‐7. - PMC - PubMed
Persson 2013
    1. Persson B, Vrethem M, Murgia N, Lindh J, Hallsten AL, Fredrikson M, et al. Urinary 2,5‐hexanedione excretion in cryptogenic polyneuropathy compared to the general Swedish population. Journal of Occupational Medicine and Toxicology 2013;8(1):21. [PUBMED: 23898939] - PMC - PubMed
Poza 1997
    1. Poza JJ, Martí‐Massó JF. Peripheral neuropathy associated with chronic obstructive pulmonary disease [Neuropatía periférica asociada a enfermedad pulmonar obstructiva crónica]. Neurología 1997;12(9):389‐94. - PubMed
Pradat 2003
    1. Pradat PF. Treatment of peripheral neuropathies with neurotrophic factors: animal models and clinical trials [Traitement des neuropathies périphériques par les facteurs neurotrophiques: des models animaux et essais thérapeutiques]. Revue Neurologique 2003;159(2):147‐61. [PUBMED: 12660566 ] - PubMed
Rajabally 2011a
    1. Rajabally YA. Neuropathy and impaired glucose tolerance: an updated review of the evidence. Acta Neurologica Scandinavica 2011;124(1):1‐8. [PUBMED: 20868430] - PubMed
Rajabally 2011b
    1. Rajabally YA, Shah RS. Dyslipidaemia in chronic acquired distal axonal polyneuropathy. Journal of Neurology 2011;258(8):1431‐6. [PUBMED: 21331599] - PubMed
Rankin 1957
    1. Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scottish Medical Journal 1957;2:200‐15. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roglio 2008
    1. Roglio I, Giatti S, Pesaresi M, Bianchi R, Cavaletti G, Lauria G, et al. Neuroactive steroids and peripheral neuropathy. Brain Research Reviews 2008;57(2):460‐9. [PUBMED: 17543391] - PubMed
Rosenberg 2004
    1. Rosenberg NR, Vermeulen M. Chronic idiopathic axonal polyneuropathy revisited. Journal of Neurology 2004;251(9):1128‐32. [PUBMED: 15372258] - PubMed
Sah 2003
    1. Sah DW, Ossipo MH, Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nature Reviews. Drug Discovery 2003;2(6):460‐72. [PUBMED: 12776221] - PubMed
Saperstein 2003
    1. Saperstein DS, Wolfe GI, Gronseth GS, Nations SP, Herbelin LL, Bryan WW, Barohn RJ. Challenges in the identification of cobalamin‐deficiency polyneuropathy. Archives of Neurology 2003;60(9):1296‐1301. - PubMed
Singer 2012
    1. Singer MA, Vernino SA, Wolfe GI. Idiopathic neuropathy: new paradigms, new promise. Journal of the Peripheral Nervous System 2012;17(Suppl 2):43‐9. [PUBMED: 22548623] - PubMed
Smith 2006
    1. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre‐diabetic neuropathy. Diabetes Care 2006;29(6):1294‐9. [PUBMED: 16732011] - PubMed
Smith 2008
    1. Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. Journal of the Neurological Sciences 2008;273(1‐2):25‐8. [PUBMED: 18606421] - PMC - PubMed
Smith 2013
    1. Smith BH, Lee J, Price C, Baranowski AP. Neuropathic pain: a pathway for care developed by the British Pain Society. British Journal of Anaesthesia 2013;111(1):73‐9. [PUBMED: 23794648] - PubMed
Streckmann 2014
    1. Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review (Provisional abstract). Sports Medicine 2014;44(9):1289‐304. [PUBMED: 24927670] - PubMed
Teunissen 2000a
    1. Teunissen LL, Eurelings M, Notermans NC, Hop JW, Gijn J. Quality of life in patients with axonal polyneuropathy. Journal of Neurology 2000;247(3):195‐9. - PubMed
Teunissen 2000b
    1. Teunissen LL, Notermans NC, Wokke JHJ. Relationship between ischemia and neuropathy. European Neurology 2000;44(1):1‐7. - PubMed
Teunissen 2000c
    1. Teunissen LL, Notermans NC, Jansen GH, Banga JD, Veldman H, Wokke JHJ. Thickness of endoneurial vessel basal lamina area in chronic idiopathic axonal polyneuropathy. Acta Neuropathologica (Berlin) 2000;100(4):445‐50. - PubMed
Teunissen 2002
    1. Teunissen LL, Franssen H, Wokke JHJ, Graaf Y, Linssen WHJP, Banga JD, et al. Is cardiovascular disease a risk factor in the development of axonal polyneuropathy?. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72(5):590‐5. - PMC - PubMed
Thompson 2015
    1. Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. Journal of Clinical Pharmacy and Therapeutics 2015;40:496‐503. [DOI: 10.1111/jcpt.12297; PUBMED: 26059975] - DOI - PubMed
Tierney 2013
    1. Tierney EF, Thurman DJ, Beckles GL, Cadwell BL. Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older. Journal of Diabetes 2013;5(2):207‐15. [PUBMED: 23121724] - PubMed
Tondel 2006
    1. Tondel M, Lindh J, Jonsson P, Vrethem M, Persson B. Occupational determinants of cryptogenic polyneuropathy. Neuroepidemiology 2006;26(4):187‐94. [PUBMED: 16569935] - PubMed
van Swieten 1988
    1. Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19(5):604‐7. - PubMed
Verghese 2001
    1. Verghese J, Bieri PL, Gellido C, Schaumburg HH, Herskovitz S. Peripheral neuropathy in young‐old and old‐old patients. Muscle & Nerve 2001;24(11):1476‐81. [PUBMED: 11745949] - PubMed
Vilming 1987
    1. Vilming ST, Stave R. Idiopathic polyneuropathy. A prospective study including gastrointestinal investigation. Journal of Oslo City Hospital 1987;37(11‐2):129‐34. - PubMed
Visser 2013
    1. Visser NA, Vrancken AFJE, Schouw YT, Berg LH, Notermans NC. Chronic idiopathic axonal polyneuropathy is associated with the metabolic syndrome. Diabetes Care 2013;36(4):817‐22. [PUBMED: 23204246] - PMC - PubMed
Visser 2014
    1. Visser NA, Notermans NC, Degen LA, Kruijk JR, Berg LH, Vrancken AFJE. Chronic idiopathic axonal polyneuropathy and vitamin B6: a controlled population‐based study. Journal of the Peripheral Nervous System 2014;19(2):136‐44. [PUBMED: 24813907] - PubMed
Visser 2015
    1. Visser NA, Notermans NC, Linssen RS, Berg LH, Vrancken AFJE. Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 2015;84(3):259‐64. [PUBMED: 25503982] - PubMed
Vrancken 2002a
    1. Vrancken AFJE, Franssen H, Wokke JHJ, Teunissen LL, Notermans NC. Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people. Archives of Neurology 2002;59(4):533‐40. - PubMed
Vrancken 2004a
    1. Vrancken AFJE, Notermans NC, Jansen GH, Wokke JHJ, Said G. Progressive idiopathic axonal neuropathy: a comparative clinical and histopathological study with vasculitic neuropathy. Journal of Neurology 2004;251(3):269‐78. - PubMed
White 2004
    1. White CM, Pritchard J, Turner‐Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003904.pub2; PUBMED: 15495069] - DOI - PubMed
White 2014
    1. White CM, Doorn PA, Garssen MPJ, Stockley RC. Interventions for fatigue in peripheral neuropathy. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD008146.pub2; PUBMED: 25519471] - DOI - PMC - PubMed
Wiffen 2013
    1. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2; PUBMED: 24217986] - DOI - PMC - PubMed
Wiffen 2014
    1. Wiffen PJ, Derry S, Moore RA, Lunn MP. Levetiracetam for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010943.pub2; PUBMED: 25000215] - DOI - PMC - PubMed
Wiffen 2015
    1. Wiffen PJ, Derry S, Moore RA, Stannard C, Aldington D, Cole P, et al. Buprenorphine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD011603.pub2; PUBMED: 26421677] - DOI - PMC - PubMed
Wolfe 1999
    1. Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, Saperstein DS, et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Archives of Neurology 1999;56:540‐7. - PubMed
Wrzosek 2015
    1. Wrzosek A, Woron J, Dobrogowski J, Jakowicka‐Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database of Systematic Reviews 2015, Issue 8. [DOI: 10.1002/14651858.CD010967.pub2; PUBMED: 26329307] - DOI - PMC - PubMed
Ziegler 2011
    1. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with α‐lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34(9):2054‐60. [PUBMED: 21775755] - PMC - PubMed
Zochodne 2005
    1. Zochodne DW, Levy D. Nitric oxide in damage, disease and repair of the peripheral nervous system. Cellular & Molecular Biology 2005;51(3):255‐67. - PubMed

References to other published versions of this review

Vrancken 2002b
    1. Vrancken A, Schaik I, Hughes R, Notermans N. Drug therapy for chronic idiopathic axonal polyneuropathy. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD003456] - DOI - PubMed
Vrancken 2004b
    1. Vrancken AFJE, Schaik IN, Hughes RAC, Notermans NC. Drug therapy for chronic idiopathic axonal polyneuropathy. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003456.pub2] - DOI - PubMed

Publication types

LinkOut - more resources